These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11287796)

  • 21. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response.
    Benkert O; Szegedi A; Wetzel H; Staab HJ; Meister W; Philipp M
    Acta Psychiatr Scand; 1997 Apr; 95(4):288-96. PubMed ID: 9150822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
    Gibiino S; Mori E; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2013 Aug; 33(4):565-9. PubMed ID: 23764690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paroxetine controlled release.
    Bang LM; Keating GM
    CNS Drugs; 2004; 18(6):355-64; discussion 365-6. PubMed ID: 15089103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder.
    Rocca P; Fonzo V; Ravizza L; Rocca G; Scotta M; Zanalda E; Bogetto F
    J Affect Disord; 2002 Aug; 70(3):313-7. PubMed ID: 12128243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses--a pilot study.
    Bäckman ML; Aberg LE; Aronen ET; Santavuori PR
    Eur J Paediatr Neurol; 2001; 5 Suppl A():163-6. PubMed ID: 11588990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient setting.
    Dennehy EB; Doyle K; Suppes T
    Int Clin Psychopharmacol; 2003 May; 18(3):143-5. PubMed ID: 12702892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes.
    Rocca P; Marchiaro L; Rasetti R; Rivoira E; Bogetto F
    Psychiatry Res; 2002 Oct; 112(2):145-52. PubMed ID: 12429360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
    Boulenger JP; Hermes A; Huusom AK; Weiller E
    Curr Med Res Opin; 2010 Mar; 26(3):605-14. PubMed ID: 20067433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine in the treatment of resistant depression.
    Caetano D; Caetano SC
    Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
    [No Abstract]   [Full Text] [Related]  

  • 31. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.
    Perna G; Bertani A; Caldirola D; Smeraldi E; Bellodi L
    Pharmacopsychiatry; 2001 May; 34(3):85-90. PubMed ID: 11434404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment of depression with paroxetine in psychiatric practice in Germany: the possibilities and current limitations of drug monitoring.
    Zaninelli R; Meister W
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):9-20. PubMed ID: 9035223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression.
    Nelson JC; Price LH; Jatlow PI
    Am J Psychiatry; 1986 Sep; 143(9):1151-4. PubMed ID: 3752299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment by paroxetine of delusional disorder, somatic type, accompanied by severe secondary depression.
    Hayashi H; Akahane T; Suzuki H; Sasaki T; Kawakatsu S; Otani K
    Clin Neuropharmacol; 2010; 33(1):48-9. PubMed ID: 19935408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.
    Parker G
    Int Clin Psychopharmacol; 2002 Mar; 17(2):87-9. PubMed ID: 11890190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptic-induced panic attacks in a patient with delusional depression.
    Bachmann KM; Modestin J
    J Nerv Ment Dis; 1987 Jun; 175(6):373-5. PubMed ID: 2884274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Tolerability of Two Different Kinds of Titration of Paroxetine Hydrocloride Solution: an Observational Study.
    Ielmini M; Poloni N; Caselli I; Bianchi L; Diurni M; Vender S; Callegari C
    Psychopharmacol Bull; 2018 Mar; 48(3):33-41. PubMed ID: 29713104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Citalopram may reduce sympathoadrenal hyperactivity in elderly depressed patients: an open multicenter study in Belgium and Luxembourg.
    Tecco J; Monreal J; Staner L
    Psychiatr Danub; 2011 Sep; 23 Suppl 1():S35-42. PubMed ID: 21894100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.